A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...
James analyst Dane Leone maintained a Strong Buy rating and a $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), aligning with the broader analyst consensus. According to InvestingPro data, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback